Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan. 

CEO
Julie So-Young Kim
CEOJulie So-Young Kim
Employees
47,029
Employees47,029
Headquarters
Osaka, Osaka
HeadquartersOsaka, Osaka
Founded
1781
Founded1781
Employees
47,029
Employees47,029

TAK Key Statistics

Market cap
58.38B
Market cap58.38B
Price-Earnings ratio
-54.73
Price-Earnings ratio-54.73
Dividend yield
3.21%
Dividend yield3.21%
Average volume
1.97M
Average volume1.97M
High today
High today
Low today
Low today
Open price
$18.29
Open price$18.29
Volume
0.00
Volume0.00
52 Week high
$18.90
52 Week high$18.90
52 Week low
$12.99
52 Week low$12.99

TAK News

Simply Wall St 5h
ORZEYFUL Approval Might Change The Case For Investing In Takeda Stock - simplywall.st

...

ORZEYFUL Approval Might Change The Case For Investing In Takeda Stock - simplywall.st
TipRanks 2d
Takeda Advances Pediatric Bleeding Disorder Program With New Vonicog Alfa Study Update

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Takeda is running a Phase 3 study called “A Study of Vonicog Alfa (rVW...

TipRanks 2d
Takeda announces publication of data from Phase 3 studies of oveporexton

Takeda (TAK) announced that the New England Journal of Medicine published results from two Phase 3 studies evaluating oveporexton, an oral orexin receptor 2 ago...

Analyst ratings

59%

of 17 ratings
Buy
58.8%
Hold
41.2%
Sell
0%

More TAK News

TipRanks 3d
Protagonist Therapeutics announces $300M share repurchase program

Protagonist Therapeutics (PTGX) announced that its board of directors has authorized a share repurchase program under which the company may repurchase up to $30...

TipRanks 7d
Takeda Backs Real‑World Fruquintinib Study in Metastatic Colorectal Cancer

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. The study Fruquintinib in Patients With Metastatic Colorectal Cancer i...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.